Atlas Trials

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT00401843 · COMPLETED

Trial details

NCT number
NCT00401843
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2006-11-28
Primary completion
2011-08-16
Enrollment
307

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.